Login to Your Account



Washington Roundup

Alexza Hopes to Balance Adasuve's Risks with REMS

By Mari Serebrov
Washington Editor

Friday, December 9, 2011
WASHINGTON – Being the first can be an uphill battle. That's what Alexza Pharmaceuticals Inc. is finding as it forges ahead with getting the first inhaled antipsychotic approved to treat agitation in patients with schizophrenia or bipolar disorder.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription